In addition, Wakamatsu et al. demonstrated that luseogliflozin ameliorated hepatic fibrosis via decreasing hepatic inflammation through suppression of monocyte chemotactic protein-1 in a model mouse for MASH [43]. The gene discussed is CCL2; the disease is Hepatic fibrosis.